MSB 3.21% $1.13 mesoblast limited

Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L, page-801

  1. 1,254 Posts.
    lightbulb Created with Sketch. 1403
    There is expert opinion that herd immunity should not be expected for Covid-19. Very technical stuff and doubtless subject to debate between researchers,
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.